Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
e137
- Development stage
- Preclinical
- Lead developer
- Pomone
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
e137 is a human monoclonal antibody developed by Pomona Ricerca for the treatment and prevention of hepatitis C virus (HCV) infection. It targets the highly conserved AR3 region of the HCV E2 envelope glycoprotein, a critical site for viral entry. By binding to this region, e137 exhibits broad-spectrum neutralizing activity against diverse HCV genotypes and strains. Currently in preclinical development, e137 is being explored as a biologic therapy to address challenges associated with direct-acting antiviral resistance and limited treatment access, often being developed alongside other antibodies like e20.
- Other names
- E137E-137E 137
02
Targets
HCV E2 (Hepatitis C virus envelope glycoprotein E2)
Beyond the preview
Go deeper on e137.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on e137.